Financhill
Buy
63

GNFT Quote, Financials, Valuation and Earnings

Last price:
$3.64
Seasonality move :
-5.9%
Day range:
$3.64 - $3.64
52-week range:
$3.11 - $6.42
Dividend yield:
0%
P/E ratio:
32.57x
P/S ratio:
2.64x
P/B ratio:
1.74x
Volume:
349
Avg. volume:
8.3K
1-year change:
3.41%
Market cap:
$181.7M
Revenue:
$30.9M
EPS (TTM):
--

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
GNFT
Genfit SA
-- -- -- -- $10.17
CLLS
Cellectis SA
$9.6M -$0.21 204.72% -100% $5.80
DBVT
DBV Technologies SA
$1.1M -$0.22 -- -59.89% $21.81
EDAP
Edap TMS SA
$20.8M -$0.11 -1.4% -21.79% $10.67
EVAX
Evaxion Biotech AS
$1.7M -$0.15 6174.51% -98% $13.25
TCBP
TC BioPharm (Holdings) PLC
-- -- -- -- --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
GNFT
Genfit SA
$3.64 $10.17 $181.7M 32.57x $0.00 0% 2.64x
CLLS
Cellectis SA
$1.23 $5.80 $122.6M -- $0.00 0% 2.90x
DBVT
DBV Technologies SA
$4.68 $21.81 $96M -- $0.00 0% --
EDAP
Edap TMS SA
$2.29 $10.67 $85M -- $0.00 0% 1.24x
EVAX
Evaxion Biotech AS
$1.87 $13.25 $11.7M -- $0.00 0% 0.52x
TCBP
TC BioPharm (Holdings) PLC
$1.75 -- $897.8K -- $0.25 0% --
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
GNFT
Genfit SA
-- 0.867 -- --
CLLS
Cellectis SA
27.15% 1.831 27.1% 1.70x
DBVT
DBV Technologies SA
-- -0.036 -- --
EDAP
Edap TMS SA
8.17% -1.273 4.48% 1.42x
EVAX
Evaxion Biotech AS
-- -2.040 -- 2.80x
TCBP
TC BioPharm (Holdings) PLC
-- -1.548 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
GNFT
Genfit SA
-- -- -- -- -- --
CLLS
Cellectis SA
-- -$10.7M -22.9% -31.46% 65.62% -$1.8M
DBVT
DBV Technologies SA
-- -$30.3M -- -- -- -$22.9M
EDAP
Edap TMS SA
$5.7M -$6.4M -39.29% -42.5% -44.53% -$6.7M
EVAX
Evaxion Biotech AS
-- -$1.7M -238.97% -- -54.59% --
TCBP
TC BioPharm (Holdings) PLC
-- -$2.6M -- -- -- -$3.5M

Genfit SA vs. Competitors

  • Which has Higher Returns GNFT or CLLS?

    Cellectis SA has a net margin of -- compared to Genfit SA's net margin of 46.57%. Genfit SA's return on equity of -- beat Cellectis SA's return on equity of -31.46%.

    Company Gross Margin Earnings Per Share Invested Capital
    GNFT
    Genfit SA
    -- -- --
    CLLS
    Cellectis SA
    -- $0.08 $179.9M
  • What do Analysts Say About GNFT or CLLS?

    Genfit SA has a consensus price target of $10.17, signalling upside risk potential of 189.3%. On the other hand Cellectis SA has an analysts' consensus of $5.80 which suggests that it could grow by 373.47%. Given that Cellectis SA has higher upside potential than Genfit SA, analysts believe Cellectis SA is more attractive than Genfit SA.

    Company Buy Ratings Hold Ratings Sell Ratings
    GNFT
    Genfit SA
    1 0 0
    CLLS
    Cellectis SA
    2 1 0
  • Is GNFT or CLLS More Risky?

    Genfit SA has a beta of 1.135, which suggesting that the stock is 13.542% more volatile than S&P 500. In comparison Cellectis SA has a beta of 3.275, suggesting its more volatile than the S&P 500 by 227.454%.

  • Which is a Better Dividend Stock GNFT or CLLS?

    Genfit SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cellectis SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genfit SA pays -- of its earnings as a dividend. Cellectis SA pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios GNFT or CLLS?

    Genfit SA quarterly revenues are --, which are smaller than Cellectis SA quarterly revenues of $12.7M. Genfit SA's net income of -- is lower than Cellectis SA's net income of $5.9M. Notably, Genfit SA's price-to-earnings ratio is 32.57x while Cellectis SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genfit SA is 2.64x versus 2.90x for Cellectis SA. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GNFT
    Genfit SA
    2.64x 32.57x -- --
    CLLS
    Cellectis SA
    2.90x -- $12.7M $5.9M
  • Which has Higher Returns GNFT or DBVT?

    DBV Technologies SA has a net margin of -- compared to Genfit SA's net margin of --. Genfit SA's return on equity of -- beat DBV Technologies SA's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    GNFT
    Genfit SA
    -- -- --
    DBVT
    DBV Technologies SA
    -- -$1.60 --
  • What do Analysts Say About GNFT or DBVT?

    Genfit SA has a consensus price target of $10.17, signalling upside risk potential of 189.3%. On the other hand DBV Technologies SA has an analysts' consensus of $21.81 which suggests that it could grow by 366.09%. Given that DBV Technologies SA has higher upside potential than Genfit SA, analysts believe DBV Technologies SA is more attractive than Genfit SA.

    Company Buy Ratings Hold Ratings Sell Ratings
    GNFT
    Genfit SA
    1 0 0
    DBVT
    DBV Technologies SA
    0 0 0
  • Is GNFT or DBVT More Risky?

    Genfit SA has a beta of 1.135, which suggesting that the stock is 13.542% more volatile than S&P 500. In comparison DBV Technologies SA has a beta of 0.707, suggesting its less volatile than the S&P 500 by 29.271%.

  • Which is a Better Dividend Stock GNFT or DBVT?

    Genfit SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genfit SA pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios GNFT or DBVT?

    Genfit SA quarterly revenues are --, which are smaller than DBV Technologies SA quarterly revenues of --. Genfit SA's net income of -- is lower than DBV Technologies SA's net income of -$30.4M. Notably, Genfit SA's price-to-earnings ratio is 32.57x while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genfit SA is 2.64x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GNFT
    Genfit SA
    2.64x 32.57x -- --
    DBVT
    DBV Technologies SA
    -- -- -- -$30.4M
  • Which has Higher Returns GNFT or EDAP?

    Edap TMS SA has a net margin of -- compared to Genfit SA's net margin of -48.85%. Genfit SA's return on equity of -- beat Edap TMS SA's return on equity of -42.5%.

    Company Gross Margin Earnings Per Share Invested Capital
    GNFT
    Genfit SA
    -- -- --
    EDAP
    Edap TMS SA
    39.35% -$0.19 $51.9M
  • What do Analysts Say About GNFT or EDAP?

    Genfit SA has a consensus price target of $10.17, signalling upside risk potential of 189.3%. On the other hand Edap TMS SA has an analysts' consensus of $10.67 which suggests that it could grow by 365.79%. Given that Edap TMS SA has higher upside potential than Genfit SA, analysts believe Edap TMS SA is more attractive than Genfit SA.

    Company Buy Ratings Hold Ratings Sell Ratings
    GNFT
    Genfit SA
    1 0 0
    EDAP
    Edap TMS SA
    1 0 0
  • Is GNFT or EDAP More Risky?

    Genfit SA has a beta of 1.135, which suggesting that the stock is 13.542% more volatile than S&P 500. In comparison Edap TMS SA has a beta of 0.372, suggesting its less volatile than the S&P 500 by 62.782%.

  • Which is a Better Dividend Stock GNFT or EDAP?

    Genfit SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edap TMS SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genfit SA pays -- of its earnings as a dividend. Edap TMS SA pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios GNFT or EDAP?

    Genfit SA quarterly revenues are --, which are smaller than Edap TMS SA quarterly revenues of $14.4M. Genfit SA's net income of -- is lower than Edap TMS SA's net income of -$7M. Notably, Genfit SA's price-to-earnings ratio is 32.57x while Edap TMS SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genfit SA is 2.64x versus 1.24x for Edap TMS SA. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GNFT
    Genfit SA
    2.64x 32.57x -- --
    EDAP
    Edap TMS SA
    1.24x -- $14.4M -$7M
  • Which has Higher Returns GNFT or EVAX?

    Evaxion Biotech AS has a net margin of -- compared to Genfit SA's net margin of -64.14%. Genfit SA's return on equity of -- beat Evaxion Biotech AS's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    GNFT
    Genfit SA
    -- -- --
    EVAX
    Evaxion Biotech AS
    -- -$0.40 $74K
  • What do Analysts Say About GNFT or EVAX?

    Genfit SA has a consensus price target of $10.17, signalling upside risk potential of 189.3%. On the other hand Evaxion Biotech AS has an analysts' consensus of $13.25 which suggests that it could grow by 608.56%. Given that Evaxion Biotech AS has higher upside potential than Genfit SA, analysts believe Evaxion Biotech AS is more attractive than Genfit SA.

    Company Buy Ratings Hold Ratings Sell Ratings
    GNFT
    Genfit SA
    1 0 0
    EVAX
    Evaxion Biotech AS
    1 0 0
  • Is GNFT or EVAX More Risky?

    Genfit SA has a beta of 1.135, which suggesting that the stock is 13.542% more volatile than S&P 500. In comparison Evaxion Biotech AS has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock GNFT or EVAX?

    Genfit SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Evaxion Biotech AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genfit SA pays -- of its earnings as a dividend. Evaxion Biotech AS pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios GNFT or EVAX?

    Genfit SA quarterly revenues are --, which are smaller than Evaxion Biotech AS quarterly revenues of $3M. Genfit SA's net income of -- is lower than Evaxion Biotech AS's net income of -$1.9M. Notably, Genfit SA's price-to-earnings ratio is 32.57x while Evaxion Biotech AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genfit SA is 2.64x versus 0.52x for Evaxion Biotech AS. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GNFT
    Genfit SA
    2.64x 32.57x -- --
    EVAX
    Evaxion Biotech AS
    0.52x -- $3M -$1.9M
  • Which has Higher Returns GNFT or TCBP?

    TC BioPharm (Holdings) PLC has a net margin of -- compared to Genfit SA's net margin of --. Genfit SA's return on equity of -- beat TC BioPharm (Holdings) PLC's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    GNFT
    Genfit SA
    -- -- --
    TCBP
    TC BioPharm (Holdings) PLC
    -- -$5.07 --
  • What do Analysts Say About GNFT or TCBP?

    Genfit SA has a consensus price target of $10.17, signalling upside risk potential of 189.3%. On the other hand TC BioPharm (Holdings) PLC has an analysts' consensus of -- which suggests that it could grow by 2642.86%. Given that TC BioPharm (Holdings) PLC has higher upside potential than Genfit SA, analysts believe TC BioPharm (Holdings) PLC is more attractive than Genfit SA.

    Company Buy Ratings Hold Ratings Sell Ratings
    GNFT
    Genfit SA
    1 0 0
    TCBP
    TC BioPharm (Holdings) PLC
    0 0 0
  • Is GNFT or TCBP More Risky?

    Genfit SA has a beta of 1.135, which suggesting that the stock is 13.542% more volatile than S&P 500. In comparison TC BioPharm (Holdings) PLC has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock GNFT or TCBP?

    Genfit SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TC BioPharm (Holdings) PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.25 per share. Genfit SA pays -- of its earnings as a dividend. TC BioPharm (Holdings) PLC pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios GNFT or TCBP?

    Genfit SA quarterly revenues are --, which are smaller than TC BioPharm (Holdings) PLC quarterly revenues of --. Genfit SA's net income of -- is lower than TC BioPharm (Holdings) PLC's net income of -$2.5M. Notably, Genfit SA's price-to-earnings ratio is 32.57x while TC BioPharm (Holdings) PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genfit SA is 2.64x versus -- for TC BioPharm (Holdings) PLC. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GNFT
    Genfit SA
    2.64x 32.57x -- --
    TCBP
    TC BioPharm (Holdings) PLC
    -- -- -- -$2.5M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is the Market Going to Go Lower?
Is the Market Going to Go Lower?

The last month has been extremely difficult for the stock…

2 Dividend Stocks to Buy in a Recession
2 Dividend Stocks to Buy in a Recession

While many economists and investors initially expected 2025 to be…

Is Ford Stock Undervalued Amid the EV Transition?
Is Ford Stock Undervalued Amid the EV Transition?

There is a lot going on in the electric vehicle…

Stock Ideas

Buy
53
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
54
Is NVDA Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 41x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Buy
52
RGC alert for Mar 18

Regencell Bioscience Holdings [RGC] is up 73.51% over the past day.

Buy
63
EXOD alert for Mar 18

Exodus Movement [EXOD] is down 3.96% over the past day.

Sell
45
MNPR alert for Mar 18

Monopar Therapeutics [MNPR] is up 0.93% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock